# antibodies .- online.com





# anti-F11R antibody (C-Term, pTyr280)

2

## **Publications**



Go to Product page

| Overview             |                                     |
|----------------------|-------------------------------------|
| Quantity:            | 100 μg                              |
| Target:              | F11R                                |
| Binding Specificity: | C-Term, pTyr280                     |
| Reactivity:          | Human                               |
| Host:                | Rabbit                              |
| Clonality:           | Polyclonal                          |
| Conjugate:           | This F11R antibody is un-conjugated |

| Application:     | Western Blotting (WB), ELISA, Fluorescence Microscopy (FM)  |
|------------------|---|
| Product Details  |   |
| Immunogen:       | Immunogen: Affinity purified Anti-JAM A pY280 antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to the cterm and phosphorylated at the tyrosine 280 position of Human JAM A protein.  Immunogen Type: Peptide   |
| Isotype:         | IgG   |
| Characteristics: | Synonyms: rabbit anti-JAM A pY280 antibody, JAM-A, Junctional adhesion molecule A, JAM-1, Junctional adhesion molecule 1, Platelet F11 receptor, Platelet adhesion molecule 1, PAM-1, CD321, JAM1, JCAM, JAM 1, JAMA  Background: Anti-JAM A pY280 was designed, produced, and validated as part of the Joy Cappel Young Investigator Award (JCYIA). JAM A pY280 Antibody detects junctional adhesion molecule A (JAM A) protein phosphorylated at the tyrosine 280 location. JAM A is involved in cell-cell contact and tight junction formation in epithelial cells. JAM A protein is a |

#### **Product Details**

transmembrane protein expressed in epithelial and endothelial cells as well as in hematopoietic cells and is important for a variety of cellular processes including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. In addition, JAM A may be a potential therapeutic target for breast cancer.

Gene Name: F11R

Purification:

Anti-JAM A pY280 is directed against human JAM A phosphorylated at the tyrosine 280 position. This product is an affinity purified antibody produced by immunoaffinity chromatography using phospho peptide coupled to agarose beads followed by solid phase adsorption(s) against non-phospho peptide to remove any unwanted reactivities. A BLAST analysis was used to suggest reactivity with this protein from human and feline based on 100% homology for the immunogen sequence.

#### Target Details

| Target:           | F11R                            |
|-------------------|---------------------------------|
| Alternative Name: | JAM A (F11R Products)           |
| Gene ID:          | 50848                           |
| NCBI Accession:   | NP_058642                       |
| Pathways:         | Cell-Cell Junction Organization |

#### **Application Details**

Application Notes: Application Note: This affinity purified antibody has been tested for use in ELISA, IF, and

western blot. Specific conditions for reactivity should be optimized by the end user. Expect a

band ~ 32.5 kDa in size corresponding to JAM A by western blotting in the appropriate cell

lysate or extract.

Western Blot Dilution: 1.0 µg/mL

ELISA Dilution: 5.0 µg/mL

IF Microscopy Dilution: User Optimized

Restrictions: For Research Use only

### Handling

Format: Liquid

Concentration: 1.95 mg/mL

## Handling

| Buffer:            | Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2<br>Stabilizer: None                                 |
|--------------------|--|
| Preservative:      | Sodium azide   |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage:           | 4 °C,-20 °C  |
| Expiry Date:       | 12 months  |
| Publications       |  |
| Product cited in:  | Mika, Luelling, Pavek, Nartker, Heyneman, Jones, Barrott: "Epigenetic Changes at the Birc5                             |
|                    | Promoter Induced by YM155 in Synovial Sarcoma." in: Journal of clinical medicine, Vol. 8,                              |
|                    | Issue 3, (2019) (PubMed).  |